Outstanding
Hyperbole, Innuendo, and Fact: The Strange Case of COX-2 Selective Inhibitors
Pediatric Rheumatology: Where Do We Go From Here?
Outcome Issues for Rheumatoid Arthritis: What Do We Have and What Do We Want?
How Meaningful Is Our Evaluation of Meaningful Change in Osteoarthritis?
Editorial commentaries
Hyperbole, Innuendo, and Fact: The Strange Case of COX-2 Selective Inhibitors
Primary Care Physicians and Musculoskeletal Disorders — The Challenges Increase
Pediatric Rheumatology: Where Do We Go From Here?
When Is a Patient with Rheumatoid Arthritis at Risk for Cardiovascular Disease?
Screening for Pulmonary Hypertension in Scleroderma: How and When to Look?
Marine Oils for Antiinflammatory Effect — Time to Take Stock
Psoriasis, Psoriatic Arthritis, or Psoriatic Disease?
Outcome Issues for Rheumatoid Arthritis: What Do We Have and What Do We Want?
Management of Whiplash-Associated Disorders — Revisiting Quebec
How Meaningful Is Our Evaluation of Meaningful Change in Osteoarthritis?
What Are Open-Label Extension Studies For?
Allogeneic Bone Marrow Transplantation for Autoimmune Disease — The Jury Is Still Out
Anti-Tumor Necrosis Factor-a Agents for Rheumatoid Arthritis: Assessing Longterm Safety
Patient Empowerment: Rofecoxib Revisited
Impaired Hypothalamic Function, Prolactinomas, and Autoimmune Diseases
Whiplash and Fibromyalgia: An Ever-Widening Gap
Improving Outcomes in Rheumatoid Arthritis: What Determines Decisions to Change Ineffective Therapy?
